Atara Biotherapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) develops off-the-shelf allogeneic T-cell immunotherapies targeting Epstein-Barr virus (EBV)-associated diseases, cancer and autoimmune conditions; its lead product, tabelecleucel (tab-cel or EBVALLO), is an EBV-specific T-cell immunotherapy approved in Europe, the UK and Switzerland for EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two years and older after at least one prior therapy, with the US FDA granting Priority Review to its Biologics License Application and a PDUFA target action date of January 10, 2026. The company's pipeline features next-generation allogeneic CAR T therapies including ATA3219, a CD19-targeted CAR T with 1XX co-stimulatory domain, memory phenotype and unedited T-cell receptor in Phase 1 for relapsed/refractory B-cell non-Hodgkin's lymphoma, lupus nephritis and systemic lupus erythematosus; ATA3431, a preclinical dual CD19/CD20 CAR T for B-cell malignancies and autoimmune diseases; and additional undisclosed preclinical AlloCAR T programs addressing oncology and autoimmune indications. Founded in 2012 and headquartered in Thousand Oaks, California, Atara leverages its EBV T-cell platform for scalable manufacturing from healthy donors, enabling rapid delivery without gene editing or HLA matching, with global operations transitioned substantially for tab-cel commercialization through its expanded partnership with Pierre Fabre Laboratories, which closed in late 2023 and includes up to $640 million in milestones, double-digit royalties and assumption of manufacturing, regulatory, clinical and commercial activities including US BLA sponsorship completed in October 2025, unlocking a $40 million milestone upon FDA approval. Recent developments encompass a 29% workforce reduction in October 2025 to retain 15 essential employees amid 60% projected operating expense cuts for 2025, board changes appointing Greg Ciongoli as Chair and adding James Huang and Nachi Subramanian while parting with three directors, a $36 million registered direct offering in September 2024, a non-binding $15 million equity line term sheet with Redmile Group, and resumed evaluation of strategic alternatives including potential mergers or acquisitions to maximize shareholder value.
Company News
Atara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
Atara Biotherapeutics Announces Changes to Its Board of Directors
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm